This research aims to investigate the expression of CLDN18.2 in invasive mucinous adenocarcinomas of the lung compared to other subtypes.
Examined CLDN18.2 expression in lung adenocarcinomas.
Compared expression levels between invasive mucinous adenocarcinomas and other major lung cancer subtypes.
CLDN18.2 is frequently expressed in invasive mucinous adenocarcinomas.
Rare expression of CLDN18.2 in other major lung cancer subtypes was observed.
Zolbetuximab may be a promising targeted therapy for these specific cancers.
Abstract
CLDN18.2 is frequently expressed in IMAs but rarely in other major lung cancer subtypes, suggesting that zolbetuximab may represent a promising targeted therapy for IMA.